Vixarelimab is a medication being studied for its potential to help people with lung conditions. In this trial, researchers are looking at how well it works for two specific lung problems: idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. These are conditions where the lungs become scarred and stiff, making it hard to breathe. Vixarelimab is being tested to see if it can improve lung function, which means helping the lungs work better and making it easier for patients to breathe. The study is comparing Vixarelimab to a placebo to see if it really makes a difference in the patients’ lung health.

Idiopathic Pulmonary Fibrosis – Idiopathic Pulmonary Fibrosis is a chronic lung disease characterized by the progressive scarring of lung tissue. This scarring, or fibrosis, leads to a gradual decline in lung function, making it increasingly difficult for the lungs to transport oxygen into the bloodstream. The disease typically begins with symptoms such as shortness of breath and a persistent dry cough. Over time, the scarring worsens, leading to more severe breathing difficulties and reduced exercise tolerance. The exact cause of the fibrosis is unknown, which is why it is termed “idiopathic.” The progression of the disease varies among individuals, with some experiencing a rapid decline in lung function.

Systemic Sclerosis-Associated Interstitial Lung Disease – Systemic Sclerosis-Associated Interstitial Lung Disease is a condition where the connective tissue disease systemic sclerosis affects the lungs, leading to inflammation and scarring of lung tissue. This interstitial lung disease results in the thickening and stiffening of the lung tissue, which impairs the lungs’ ability to function properly. Patients may experience symptoms such as shortness of breath, a persistent cough, and fatigue. As the disease progresses, lung function continues to decline, leading to increased respiratory difficulties. The extent and rate of progression can vary significantly among individuals. The lung involvement is a significant aspect of systemic sclerosis, impacting overall health and quality of life.